Abstract
Monoclonal anti-IgE antibody omalizumab is a promising therapeutic option in patients with chronic urticaria resistant to non-sedating H1-antihistamines. However, data about its long-term efficacy and safety are still scant, especially from the Middle East. We describe the long-term clinical course of patients with severe recalcitrant chronic urticaria that was treated with omalizumab in our allergy center in Kuwait, for periods up to 4 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
